Anti‑survival and pro‑apoptotic effects of meridianin C derivatives on MV4‑11 human acute myeloid leukemia cells

Cho,Hyorim; Yadav,Anil   Kumar; Do,Youngrok; Heo,Mihwa; Bishop‑Bailey,David; Lee,Jinho; Jang,Byeong‑Churl

doi:10.3892/ijo.2019.4925

Anti‑survival and pro‑apoptotic effects of meridianin C derivatives on MV4‑11 human acute myeloid leukemia cells

Authors:
- Hyorim Cho
- Anil Kumar Yadav
- Youngrok Do
- Mihwa Heo
- David Bishop‑Bailey
- Jinho Lee
- Byeong‑Churl Jang
View Affiliations

Affiliations: Department of Molecular Medicine, College of Medicine, Keimyung University, Daegu 42601, Republic of Korea, Department of Hematology and Oncology, College of Medicine, Keimyung University, Daegu 42601, Republic of Korea, Comparative Biomedical Sciences, Royal Veterinary College, London NW 10TU, United Kingdom, Department of Chemistry, College of Life Science, Keimyung University, Daegu 42601, Republic of Korea
Published online on: November 27, 2019 https://doi.org/10.3892/ijo.2019.4925
Pages: 368-378

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Meridianin C is a marine natural product with anticancer activity. Several meridianin C derivatives (compounds 7a‑j) were recently synthesized, and their inhibitory effects on pro‑viral integration site for Moloney murine leukemia virus (PIM) kinases, as well as their antiproliferative effects on human leukemia cells, were reported. However, the anti‑leukemic effects and mechanisms of action of meridianin C and its derivatives remain largely unknown. The aim of the present study was to investigate the effects of meridianin C and its derivatives on MV4‑11 human acute myeloid leukemia cell growth. The parent compound meridianin C did not markedly affect the viability and survival of MV4‑11 cells. By contrast, MV4‑11 cell viability and survival were reduced by meridianin C derivatives, with compound 7a achieving the most prominent reduction. Compound 7a notably inhibited the expression and activity of PIM kinases, as evidenced by reduced B‑cell lymphoma‑2 (Bcl‑2)‑associated death promoter phosphorylation at Ser112. However, meridianin C also suppressed PIM kinase expression and activity, and the pan‑PIM kinase inhibitor AZD1208 only slightly suppressed the survival of MV4‑11 cells. Thus, the anti‑survival effect of compound 7a on MV4‑11 cells was unrelated to PIM kinase inhibition. Moreover, compound 7a induced apoptosis, caspase‑9 and ‑3 activation and poly(ADP‑ribose) polymerase (PARP) cleavage, but did not affect death receptor (DR)‑4 or DR‑5 expression in MV4‑11 cells. Compound 7a also induced the generation of cleaved Bcl‑2, and the downregulation of myeloid cell leukemia (Mcl)‑1 and X‑linked inhibitor of apoptosis (XIAP) in MV4‑11 cells. Furthermore, compound 7a increased eukaryotic initiation factor (eIF)‑2α phosphorylation and decreased S6 phosphorylation, whereas GRP‑78 expression was unaffected. Importantly, treatment with a pan‑caspase inhibitor (z‑VAD‑fmk) significantly attenuated compound 7a‑induced apoptosis, caspase‑9 and ‑3 activation, PARP cleavage, generation of cleaved Bcl‑2 and downregulation of Mcl‑1 and XIAP in MV4‑11 cells. Collectively, these findings demonstrated the strong anti‑survival and pro‑apoptotic effects of compound 7a on MV4‑11 cells through regulation of caspase‑9 and ‑3, Bcl‑2, Mcl‑1, XIAP, eIF‑2α and S6 molecules.

View Figures

View References

1	Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, Andreeff M, Coombes KR and Mills GB: Functional proteomic profiling of AML predicts response and survival. Blood. 113:154–164. 2009. View Article : Google Scholar
2	Short NJ, Rytting ME and Cortes JE: Acute myeloid leukaemia. Lancet. 392:593–606. 2018. View Article : Google Scholar : PubMed/NCBI
3	National Cancer Institute: Cancer Stat Facts: Leukemia. https://seer.cancer.gov/statfacts/html/leuks.html Accessed March 2, 2019.
4	Ossenkoppele G and Löwenberg B: How I treat the older patient with acute myeloid leukemia. Blood. 125:767–774. 2015. View Article : Google Scholar
5	Wyllie AH, Kerr JF and Currie AR: Cell death: The significance of apoptosis. Int Rev Cytol. 68:251–306. 1980. View Article : Google Scholar : PubMed/NCBI
6	Chen Q, Kang J and Fu C: The independence of and associations among apoptosis, autophagy, and necrosis. Signal Transduct Target Ther. 3:182018. View Article : Google Scholar : PubMed/NCBI
7	Cohen GM: Caspases: The executioners of apoptosis. Biochem J. 326:1–16. 1997. View Article : Google Scholar : PubMed/NCBI
8	Deveraux QL and Reed JC: IAP family proteins--suppressors of apoptosis. Genes Dev. 13:239–252. 1999. View Article : Google Scholar : PubMed/NCBI
9	Kale J, Osterlund EJ and Andrews DW: BCL-2 family proteins: Changing partners in the dance towards death. Cell Death Differ. 25:65–80. 2018. View Article : Google Scholar : PubMed/NCBI
10	Jang BC, Paik JH, Jeong HY, Oh HJ, Park JW, Kwon TK, Song DK, Park JG, Kim SP, Bae JH, et al: Leptomycin B-induced apoptosis is mediated through caspase activation and down-regulation of Mcl-1 and XIAP expression, but not through the generation of ROS in U937 leukemia cells. Biochem Pharmacol. 68:263–274. 2004. View Article : Google Scholar : PubMed/NCBI
11	Rao J, Xu DR, Zheng FM, Long ZJ, Huang SS, Wu X, Zhou WH, Huang RW and Liu Q: Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells. J Transl Med. 9:712011. View Article : Google Scholar : PubMed/NCBI
12	Kitada S, Zapata JM, Andreeff M and Reed JC: Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood. 96:393–397. 2000. View Article : Google Scholar : PubMed/NCBI
13	Luedtke DA, Niu X, Pan Y, Zhao J, Liu S, Edwards H, Chen K, Lin H, Taub JW and Ge Y: Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Signal Transduct Target Ther. 2:170122017. View Article : Google Scholar : PubMed/NCBI
14	Nawijn MC, Alendar A and Berns A: For better or for worse: The role of Pim oncogenes in tumorigenesis. Nat Rev Cancer. 11:23–34. 2011. View Article : Google Scholar
15	Decker S, Finter J, Forde AJ, Kissel S, Schwaller J, Mack TS, Kuhn A, Gray N, Follo M, Jumaa H, et al: PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1). Mol Cancer Ther. 13:1231–1245. 2014. View Article : Google Scholar : PubMed/NCBI
16	Lu J, Zavorotinskaya T, Dai Y, Niu XH, Castillo J, Sim J, Yu J, Wang Y, Langowski JL, Holash J, et al: Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood. 122:1610–1620. 2013. View Article : Google Scholar : PubMed/NCBI
17	Gómez-Abad C, Pisonero H, Blanco-Aparicio C, Roncador G, González-Menchén A, Martinez-Climent JA, Mata E, Rodríguez ME, Muñoz-González G, Sánchez-Beato M, et al: PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. Blood. 118:5517–5527. 2011. View Article : Google Scholar : PubMed/NCBI
18	Guo S, Mao X, Chen J, Huang B, Jin C, Xu Z and Qiu S: Overexpression of Pim-1 in bladder cancer. J Exp Clin Cancer Res. 29:1612010. View Article : Google Scholar : PubMed/NCBI
19	Wang J, Anderson PD, Luo W, Gius D, Roh M and Abdulkadir SA: Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells. Oncogene. 31:1794–1803. 2012. View Article : Google Scholar
20	Keane NA, Reidy M, Natoni A, Raab MS and O'Dwyer M: Targeting the Pim kinases in multiple myeloma. Blood Cancer J. 5:e3252015. View Article : Google Scholar : PubMed/NCBI
21	Yadav AK, Kumar V, Bailey DB and Jang BC: AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK. Int J Mol Sci. 20:22019. View Article : Google Scholar
22	Cervantes-Gomez F, Chen LS, Orlowski RZ and Gandhi V: Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma. Clin Lymphoma Myeloma Leuk. 13(Suppl 2): S317–S329. 2013. View Article : Google Scholar : PubMed/NCBI
23	Gompel M, Leost M, De Kier Joffe EB, Puricelli L, Franco LH, Palermo J and Meijer L: Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum. Bioorg Med Chem Lett. 14:1703–1707. 2004. View Article : Google Scholar : PubMed/NCBI
24	Bharate SB, Yadav RR, Battula S and Vishwakarma RA: Meridianins: Marine-derived potent kinase inhibitors. Mini Rev Med Chem. 12:618–631. 2012. View Article : Google Scholar : PubMed/NCBI
25	Giraud F, Alves G, Debiton E, Nauton L, Théry V, Durieu E, Ferandin Y, Lozach O, Meijer L, Anizon F, et al: Synthesis, protein kinase inhibitory potencies, and in vitro antiproliferative activities of meridianin derivatives. J Med Chem. 54:4474–4489. 2011. View Article : Google Scholar : PubMed/NCBI
26	Radwan MA and El-Sherbiny M: Synthesis and antitumor activity of indolylpyrimidines: Marine natural product meridianin D analogues. Bioorg Med Chem. 15:1206–1211. 2007. View Article : Google Scholar
27	More KN, Jang HW, Hong VS and Lee J: Pim kinase inhibitory and antiproliferative activity of a novel series of meridianin C derivatives. Bioorg Med Chem Lett. 24:2424–2428. 2014. View Article : Google Scholar : PubMed/NCBI
28	Park NS, Park YK, Ramalingam M, Yadav AK, Cho HR, Hong VS, More KN, Bae JH, Bishop-Bailey D, Kano J, et al: Meridianin C inhibits the growth of YD-10B human tongue cancer cells through macropinocytosis and the down-regulation of Dickkopf-related protein-3. J Cell Mol Med. 22:5833–5846. 2018. View Article : Google Scholar : PubMed/NCBI
29	Drexler HG, MacLeod RA and Uphoff CC: Leukemia cell lines: In vitro models for the study of Philadelphia chromosome-positive leukemia. Leuk Res. 23:207–215. 1999.PubMed/NCBI
30	Meshinchi S and Appelbaum FR: Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res. 15:4263–4269. 2009. View Article : Google Scholar : PubMed/NCBI
31	Macdonald A, Campbell DG, Toth R, McLauchlan H, Hastie CJ and Arthur JS: Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. BMC Cell Biol. 7:12006. View Article : Google Scholar : PubMed/NCBI
32	Keeton EK, McEachern K, Dillman KS, Palakurthi S, Cao Y, Grondine MR, Kaur S, Wang S, Chen Y, Wu A, et al: AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 123:905–913. 2014. View Article : Google Scholar :
33	Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, et al: Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 25:486–541. 2018. View Article : Google Scholar : PubMed/NCBI
34	Festjens N, van Gurp M, van Loo G, Saelens X and Vandenabeele P: Bcl-2 family members as sentinels of cellular integrity and role of mitochondrial intermembrane space proteins in apoptotic cell death. Acta Haematol. 111:7–27. 2004. View Article : Google Scholar
35	Zhang B, Gojo I and Fenton RG: Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood. 99:1885–1893. 2002. View Article : Google Scholar : PubMed/NCBI
36	Bose P and Grant S: Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML). Leuk Res Rep. 2:12–14. 2013.PubMed/NCBI
37	Cheng EH, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A, Ueno K and Hardwick JM: Conversion of Bcl-2 to a Bax-like death effector by caspases. Science. 278:1966–1968. 1997. View Article : Google Scholar
38	Kirsch DG, Doseff A, Chau BN, Lim DS, de Souza-Pinto NC, Hansford R, Kastan MB, Lazebnik YA and Hardwick JM: Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J Biol Chem. 274:21155–21161. 1999. View Article : Google Scholar : PubMed/NCBI
39	Kapoor S, Natarajan K, Baldwin PR, Doshi KA, Lapidus RG, Mathias TJ, Scarpa M, Trotta R, Davila E, Kraus M, et al: Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation. Clin Cancer Res. 24:234–247. 2018. View Article : Google Scholar
40	Kasper S, Breitenbuecher F, Heidel F, Hoffarth S, Markova B, Schuler M and Fischer T: Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies. Blood Cancer J. 2. pp. e602012, View Article : Google Scholar
41	Deveraux QL, Takahashi R, Salvesen GS and Reed JC: X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 388:300–304. 1997. View Article : Google Scholar : PubMed/NCBI
42	Shiozaki EN, Chai J, Rigotti DJ, Riedl SJ, Li P, Srinivasula SM, Alnemri ES, Fairman R and Shi Y: Mechanism of XIAP-mediated inhibition of caspase-9. Mol Cell. 11:519–527. 2003. View Article : Google Scholar : PubMed/NCBI
43	Han M, Gao H, Xie J, Yuan YP, Yuan Q, Gao MQ, Liu KL, Chen XH, Han YT and Han ZW7: Hispidulin induces ER stress-mediated apoptosis in human hepatocellular carcinoma cells in vitro and in vivo by activating AMPK signaling pathway. Acta Pharmacol Sin. 40:666–676. 2019. View Article : Google Scholar
44	de Haro C, Méndez R and Santoyo J: The eIF-2alpha kinases and the control of protein synthesis. FASEB J. 10:1378–1387. 1996. View Article : Google Scholar : PubMed/NCBI
45	Ruvinsky I and Meyuhas O: Ribosomal protein S6 phos-phorylation: From protein synthesis to cell size. Trends Biochem Sci. 31:342–348. 2006. View Article : Google Scholar : PubMed/NCBI
46	Chen B, Tan Z, Gao J, Wu W, Liu L, Jin W, Cao Y, Zhao S, Zhang W, Qiu Z, et al: Hyperphosphorylation of ribosomal protein S6 predicts unfavorable clinical survival in non-small cell lung cancer. J Exp Clin Cancer Res. 34:1262015. View Article : Google Scholar : PubMed/NCBI